MAVENIR
11.3.2022 08:02:12 CET | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, announced today that together with O2 Telefónica, have demonstrated simplified deployment and change management on Core network elements, leveraging a common Zero Touch Continuous Integration, Continuous Deployment and Continuous Testing (CI/CD/CT) framework in O2 Telefónica’s German network. This will streamline operations in O2 Telefónica OpCos with leaner operations, faster deployments, and simplified operational changes in the network.
This is a significant milestone in the evolution of streamlined operations, moving away from manual deployments and reducing human error. CI/CD provides greater flexibility for customers in day-to-day Operations and is expected to deliver significant benefits in terms of speed and cost of deployment.
Mavenir will work with O2 Telefónica to automate the Network Operations, enabling the transition to the adoption of the virtualized Network Functions. Mavenir’s CI/CD/CT framework will allow for creating customized workflows/processes for fast, agile change management in increased complexity 4G/5G networks. Mavenir’s solution is Opensource-based, interoperable, standardized technology that can be integrated in a “plug and play” manner for any VNF functions.
“5G requires cloud-native and microservices architecture but brings along more operational complexity in the network. CI/CD/CT based zero-touch deployment and change management is our way to be agile and accelerate time to market. This is a key strategy in the path of automation of our networks to achieve leaner and meaner Operations. Mavenir is a trusted and reliable partner for this journey, given the know-how and the experience we have with them in Core & Cloud projects,” said Jochen Bockfeld, Director Common Services, O2 Telefónica Deutschland .
Omar Shahdad, Senior Vice President Global Operations, Mavenir said, “We are honored to have been chosen by O2 Telefónica for this vital part of their network simplification journey. Mavenir is uniquely qualified to provide CI/CD services in the Telco space due to our extensive know-how spanning multiple Telco domains. We are a company that prides itself in its speed, agility, responsiveness, and those are the same required characteristics of a CI/CD program. Mavenir’s solution utilizes high levels of automation and integration that enables our customers to harness the benefits of cloud-native and virtual networks to manage complexity and allow hybrid operations for increased flexibility.”
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
About O2 Telefónica:
O2 Telefónica Deutschland offers telecommunications services for consumers and business customers as well as innovative digital products and services in the area of the Internet of Things and data analytics. The company is one of the leading integrated telecommunications providers in Germany. In mobile communications alone, O2 Telefónica serves more around 46 million mobile lines (incl. M2M - as of 31.12.2021). No network operator connects more people in this country. Under its core brand O2 and various secondary and partner brands, the company sells postpaid and prepaid mobile communications products with innovative mobile data services. The basis for this is the mobile communications network based on a highly resilient GSM, UMTS and LTE infrastructure. At the same time, the company is building a powerful and energy-efficient 5G network. O2 Telefónica also provides telephony and high-speed Internet products based on various technologies in the fixed-network area. Telefónica Deutschland Holding AG has been listed in the Prime Standard segment of the Frankfurt Stock Exchange (TecDAX) since 2012. In the 2021 financial year, the company generated revenue of EUR 7,8 billion with around 7.400 employees. The company is majority-owned by the Spanish telecommunications group Telefónica S.A., headquartered in Madrid. With business activities in 14 countries and a customer base of around 369 million lines, the Group is one of the world's largest telecommunications providers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220310005203/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom